Search company, investor...

Evergreen Theragnostics

Founded Year



Series B | Alive

Total Raised


Last Raised

$15M | 11 days ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+160 points in the past 30 days

About Evergreen Theragnostics

Evergreen Theragnostics is a radiopharmaceutical contract development and manufacturing organization that provides theragnostic services. It offers services for therapeutic and centrally distributed diagnostic radiopharmaceuticals, from early development through commercialization. The company was founded in 2019 and is based in Springfield, New Jersey.

Headquarters Location

27 Commerce Street

Springfield, New Jersey, 07081,

United States


Missing: Evergreen Theragnostics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Evergreen Theragnostics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Evergreen Theragnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Evergreen Theragnostics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Evergreen Theragnostics News

Evergreen Theragnostics Closes $15M Series B Funding

Mar 15, 2023

Evergreen Theragnostics , a Springfield, NJ-based clinical stage contract development and manufacturing organization (CDMO), raised $15M in Series B funding. The backers were nor disclosed. The company intends to use the funds to prepare for the launch of Ga-68 DOTATOC, if approved. Activities will include building commercial capabilities and staffing, as well as inventory build. The product is planned to be available through Evergreen’s radiopharmacy partners around the country. Founded in 2019 and led by James Cook, President and CEO, Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals, being engaged in three core areas: CDMO, Products, and Drug Discovery. Leveraging the capital raise, the company is launching a new business unit, Evergreen Discovery, which is focused on developing novel radiopharmaceuticals for cancer therapy. To support its new business unit, Evergreen has recruited Dr. Thomas Reiner as their Chief Scientific Officer. Prior to this, Dr. Reiner served as Head of Radioligand Therapy Drug Discovery on the Executive Leadership Team of AAA (Advanced Accelerator Applications, a Novartis Company). He is a former Laboratory Head, Associate Professor and Member of the Chemical Biology Program at Memorial Sloan Kettering Cancer Center. Evergreen Discovery will be based in a new research facility near Princeton, NJ, opening in Q3’2023. FinSMEs

Evergreen Theragnostics Frequently Asked Questions (FAQ)

  • When was Evergreen Theragnostics founded?

    Evergreen Theragnostics was founded in 2019.

  • Where is Evergreen Theragnostics's headquarters?

    Evergreen Theragnostics's headquarters is located at 27 Commerce Street, Springfield.

  • What is Evergreen Theragnostics's latest funding round?

    Evergreen Theragnostics's latest funding round is Series B.

  • How much did Evergreen Theragnostics raise?

    Evergreen Theragnostics raised a total of $34.05M.

  • Who are the investors of Evergreen Theragnostics?

    Investors of Evergreen Theragnostics include Club degli Investitori and Bank of America.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.